Search Results - "KANZLER, S" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

by Moehler, M, Maderer, A, Schimanski, C, Kanzler, S, Denzer, U, Kolligs, F.T, Ebert, M.P, Distelrath, A, Geissler, M, Trojan, J, Schütz, M, Berie, L, Sauvigny, C, Lammert, F, Lohse, A, Dollinger, M.M, Lindig, U, Duerr, E.M, Lubomierski, N, Zimmermann, S, Wachtlin, D, Kaiser, A.-K, Schadmand-Fischer, S, Galle, P.R, Woerns, M
Published in European journal of cancer (1990) (01.12.2014)

Get full text

Journal Article

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study

by Moehler, M., Mueller, A., Trarbach, T., Lordick, F., Seufferlein, T., Kubicka, S., Geißler, M., Schwarz, S., Galle, P.R., Kanzler, S.
Published in Annals of oncology (01.06.2011)

Get full text

Journal Article

$Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer$

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

by TRARBACH, T, MOEHLER, M, HEINEMANN, V, KÖHNE, C.-H, PRZYBOREK, M, SCHULZ, C, SNELLER, V, GALLANT, G, KANZLER, S
Published in British journal of cancer (02.02.2010)

Get full text

Journal Article

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

by Haas, M., Waldschmidt, D.T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Fischer von Weikersthal, L., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C.B., Held, S., von Bergwelt-Baildon, M., Boeck, S., Heinemann, V.
Published in European journal of cancer (1990) (01.03.2021)

Get full text

Journal Article

Recommendation for severity assessment following liver resection and liver transplantation in rats: Part I

Recommendation for severity assessment following liver resection and liver transplantation in rats: Part I

by Kanzler, S, Rix, A, Czigany, Z, Tanaka, H, Fukushima, K, Kögel, B, Pawlowsky, K, Tolba, R H
Published in Laboratory animals (London) (01.12.2016)

Get full text

Journal Article

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

by Haas, M., Siveke, J.T., Schenk, M., Lerch, M.M., Caca, K., Freiberg-Richter, J., Fischer von Weikersthal, L., Kullmann, F., Reinacher-Schick, A., Fuchs, M., Kanzler, S., Kunzmann, V., Ettrich, T.J., Kruger, S., Westphalen, C.B., Held, S., Heinemann, V., Boeck, S.
Published in European journal of cancer (1990) (01.05.2018)

Get full text

Journal Article

Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)

Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)

by Geissler, M., Tannapfel, A., Reinacher-Schick, A., Martens, U., Ricke, J., Riera-Knorrenschield, J., Kanzler, S., Held, S., Heinemann, V., Seufferlein, T., Modest, D.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)

1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109)

by Geissler, M, Klingler, T, Riera Knorrenschild, J, Tannapfel, A, Greeve, J, Seufferlein, T, Kanzler, S, Held, S, Heinemann, V, Reinacher-Schick, A, Martens, U M
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

by Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C., Modest, D. P.
Published in Journal of cancer research and clinical oncology (01.10.2020)

Get full text

Journal Article

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

by Schmoll, H., Garlipp, B., Junghanß, C., Vogel, A., Kaiser, U., Florschütz, A., Kanzler, S., Hannig, C., Meinert, F., Cygon, F., Stein, A.
Published in Annals of oncology (01.06.2018)

Get full text

Journal Article

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

by Geissler, M., Klingler, T., Riera-Knorrenschield, J., Tannapfel, A., Seufferlein, T., Held, S., Florschütz, A., Kanzler, S., Heinemann, V., Reinacher-Schick, A., Martens, U.
Published in Annals of oncology (01.06.2018)

Get full text

Journal Article

Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)

Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)

by Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R.J.C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C.B., Kruger, S., Boeck, S., Heinemann, V.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction

by Moehler, M., Kanzler, S., Geissler, M., Raedle, J., Ebert, M. P., Daum, S., Flieger, D., Seufferlein, T., Galle, P. R., Hoehler, T.
Published in Annals of oncology (01.01.2010)

Get full text

Journal Article

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

by HOEHLER, T, VON WICHERT, G, HALLEK, M, HOFHEINZ, R, HACKER, U. T, SCHIMANSKI, C, KANZLER, S, MOEHLER, M. H, HINKE, A, SEUFFERLEIN, T, SIEBLER, J, HOCHHAUS, A, ARNOLD, D
Published in British journal of cancer (17.09.2013)

Get full text

Journal Article

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

by Martens, U.M, Wessendorf, S, Knorrenschild, J. Riera, Buechner-Steudel, P, Florschuetz, A, Atzpodien, J, Greeve, J, Kanzler, S, Ettrich, T, Lindig, U, Egger, M, Hebart, H, Geissler, M
Published in European journal of cancer (1990) (01.09.2015)

Get full text

Journal Article

Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice

Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice

by Feng, T, Dzieran, J, Yuan, X, Dropmann, A, Maass, T, Teufel, A, Marhenke, S, Gaiser, T, Rückert, F, Kleiter, I, Kanzler, S, Ebert, M P, Vogel, A, Ten Dijke, P, Dooley, S, Meindl-Beinker, N M
Published in Oncogenesis (New York, NY) (01.01.2017)

Get full text

Journal Article

In vivo confocal laser endomicroscopy of the human liver: a novel method for assessing liver microarchitecture in real time

In vivo confocal laser endomicroscopy of the human liver: a novel method for assessing liver microarchitecture in real time

by Goetz, M, Kiesslich, R, Dienes, H-P, Drebber, U, Murr, E, Hoffman, A, Kanzler, S, Galle, P R, Delaney, P, Neurath, M F
Published in Endoscopy (01.07.2008)

Get more information

Journal Article

Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma

Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma

by Herber, S, Otto, G, Schneider, J, Manzl, N, Kummer, I, Kanzler, S, Schuchmann, A, Thies, J, Düber, C, Pitton, M
Published in Cardiovascular and interventional radiology (01.11.2007)

Get full text

Journal Article

Involvement of β3-adrenergic receptors in the control of food intake in rats

Involvement of β3-adrenergic receptors in the control of food intake in rats

by Kanzler, S A, Januario, A C, Paschoalini, M A
Published in Brazilian journal of medical and biological research (01.11.2011)

Get full text

Journal Article

In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases

In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases

by Goetz, M, Fottner, C, Schirrmacher, E, Delaney, P, Gregor, S, Schneider, C, Strand, D, Kanzler, S, Memadathil, B, Weyand, E, Holtmann, M, Schirrmacher, R, Weber, M M, Anlauf, M, Klöppel, G, Vieth, M, Galle, P R, Bartenstein, P, Neurath, M F, Kiesslich, R
Published in Endoscopy (01.04.2007)

Get more information

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[12]